These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22881992)

  • 1. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC
    Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab--a single centre experience in eastern India.
    Patel S; Purohit P; Mashon RS; Dehury S; Meher S; Sahoo S; Dash SS; Das K; Das P; Patel DK
    Pediatr Blood Cancer; 2014 Aug; 61(8):1341-6. PubMed ID: 24616059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
    Al-Nood HA; Al-Khawlani MM; Al-Akwa A
    Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
    Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea in children: present and future.
    Vichinsky EP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K; Smith-Whitley K
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
    Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT
    Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
    Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
    Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
    Dehury S; Purohit P; Patel S; Meher S; Kullu BK; Sahoo LK; Patel NK; Mohapatra AK; Das K; Patel DK
    Pediatr Blood Cancer; 2015 Jun; 62(6):1017-23. PubMed ID: 25546091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of hydroxyurea on hemoglobin S].
    Torres AF; Eberle SE; Sciuccati G; Bonduel M
    Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
    Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C
    Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.